University Hospital Erlangen, Erlangen – Germany
About Prof. Dr. Andreas Mackensen
Prof. Dr. med. Andreas Mackensen is an internationally renowned Hematologist and Oncologist with 33+ years of clinical and research experience and a focused practice in CAR-T cell therapy, hematological malignancies, allogeneic stem-cell transplantation and cellular immunotherapy. He is Director of Department of Medicine 5 — Hematology and Oncology at Uniklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Deputy Director of CCC Erlangen-EMN, Active President of the Bavarian Cancer Research Center (BZKF) and a founding director since 2019. Erlangen is one of the few academic centres permitted to produce CAR-T cells in Europe under his leadership. He is widely regarded as one of the leading Hematologist specialists in Erlangen, Germany for international patients seeking CAR-T cell therapy and advanced hematological care.
- 33+ years of clinical and research experience in hematology, oncology and cellular immunotherapy
- Director — Department of Medicine 5 (Hematology & Oncology), Uniklinikum Erlangen, FAU
- Deputy Director — Comprehensive Cancer Center (CCC) Erlangen-EMN
- Active President & Founding Director — Bavarian Cancer Research Center (BZKF) (since 2019)
- Member of the Supervisory Board, Uniklinikum Erlangen (since 2012)
- Pioneer of CAR-T cell therapy for autoimmune diseases (CASTLE study, 2021)
Qualifications & Credentials
Medical Degrees
- Studies in Human Medicine (Graduation) — Albert-Ludwigs-University of Freiburg, Germany, 1981–1988
- Medical-Technical Laboratory Assistant Training — Germany, 1981 (prior to medical studies)
- Doctorate (Dr. med.) — Germany
- Habilitation (Venia Legendi) — Germany
- Professor (Univ.-Prof.) of Internal Medicine — FAU Erlangen-Nürnberg
Fellowships & Special Training
- Specialist Certification (Facharzt) — Internal Medicine, Hematology & Medical Oncology
- Sub-specialty training in Stem-Cell Transplantation, CAR-T Cell Therapy and Cellular Immunotherapy
- Continuing professional development in immunotherapy, allogeneic SCT and clinical trial design
Certifications & Accreditations
- Bavarian State Medical Council — Registered Specialist in Internal Medicine, Hematology and Oncology
- Active President — Bavarian Cancer Research Center (BZKF)
- Speaker / Co-speaker of multiple DFG-funded research programmes (KFO146, TRR221)
Areas of Expertise
Major Conditions Treated
- Acute Lymphoblastic Leukaemia (ALL) & Acute Myeloid Leukaemia (AML)
- Chronic Lymphocytic Leukaemia (CLL) & Chronic Myeloid Leukaemia (CML)
- Hodgkin and Non-Hodgkin Lymphomas (Including B-Cell NHL)
- Multiple Myeloma
- Myelodysplastic Syndromes (MDS)
- Aplastic Anaemia & Bone-Marrow Failure Syndromes
- Bleeding & Coagulation Disorders
- Severe Autoimmune Diseases Eligible for CAR-T (Lupus, Systemic Sclerosis, Autoimmune Myositis)
- Selected Solid Tumours (Coordinated through CCC Erlangen-EMN)
- Patients Eligible for Autologous & Allogeneic Stem-Cell Transplantation
Sub-specialties
- CAR-T Cell Therapy & Cellular Immunotherapy: CD19-directed CAR-T, BCMA-directed CAR-T, IL-18-enforced CAR-T, double CAR-T strategies for hematological malignancies and severe autoimmune diseases — making him a leading Hematologist specialist Erlangen, Germany for CAR-T cell therapy.
- Allogeneic Stem-Cell Transplantation & Leukaemia: Allogeneic and autologous SCT, GvHD/GvL management and clinical translation through DFG TRR221 — supporting demand for the best Hematologist doctor in Germany for stem-cell transplantation.
- Lymphoma, Myeloma & Solid-Tumour Immunotherapy: B-cell lymphomas, multiple myeloma and CAR-T research for solid cancers (including GD2-positive solid tumours).
Advanced Procedures & Treatments
- CD19-Directed CAR-T Cell Therapy
- BCMA-Directed CAR-T Cell Therapy
- Cytokine-Engineered (IL-18-Armoured) CAR-T Cells
- Double CAR-T Cell Therapy (Selected Cases)
- Autologous Hematopoietic Stem-Cell Transplantation
- Allogeneic Hematopoietic Stem-Cell Transplantation
- Donor Lymphocyte Infusion (DLI)
- Standard & Investigational Chemotherapy
- Immunotherapy & Checkpoint Inhibitors
- Targeted Therapy (BCR Inhibitors, BCL-2 Inhibitors, BiTE)
- Multidisciplinary Tumour Board Coordination
- Phase I / II / III Clinical Trials in Hematology & Cellular Therapy
List of Disease and Treatment for which Prof. Dr. Andreas Mackensen can be consulted
Professional Experience
Current Affiliation
- Director — Department of Medicine 5 (Hematology & Oncology), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) (Present)
- Director — Transplant Center, Universitätsklinikum Erlangen (Present)
- Deputy Director — Comprehensive Cancer Center (CCC) Erlangen-EMN (Present)
- Active President & Founding Director — Bavarian Cancer Research Center (BZKF) (Present)
- Univ.-Prof. of Internal Medicine — FAU Erlangen-Nürnberg (Present)
- Speaker for Erlangen — DFG Collaborative Research Center (CRC) Transregio TRR221 (Present)
Past Affiliations
- Albert-Ludwigs-University of Freiburg — Medical Studies, 1981–1988
- Spokesman and Head — Clinical Research Group KFO146, DFG (Past)
- Co-speaker — Transregio SFB TRR221, DFG (Continuing)
- Member of Supervisory Board, Uniklinikum Erlangen (since 2012 – Present)
Academic & Research Roles
- Univ.-Prof. of Internal Medicine — FAU Erlangen-Nürnberg
- Founding Director, Bavarian Cancer Research Center (BZKF), 2019
- Spokesman and Head — Clinical Research Group KFO146 (DFG)
- Co-speaker — DFG Transregio SFB TRR221
- Erlangen is one of the few academic centres permitted to produce CAR-T cells in Europe (since 2019) — under his leadership
- Author of high-impact publications in Nature Medicine, The New England Journal of Medicine, Lancet and Blood
Key Achievements
- Pioneer of CAR-T cell therapy for severe autoimmune diseases (with Prof. Georg Schett — Erlangen CASTLE study, 2021)
- Vincenz Czerny Prize — German Society of Hematology and Oncology (DGHO), Vienna, 1994
- Young Investigator Award — International Association for Endotoxin Research, San Diego, 1990
- Active President & Founding Director, Bavarian Cancer Research Center (BZKF)
- Built the Erlangen CAR-T cell production and clinical programme — one of the few European academic CAR-T sites
Awards & Recognitions
National & International Awards
- Young Investigator Award — International Association for Endotoxin Research, San Diego, USA (1990)
- Vincenz Czerny Prize — German Society of Hematology and Oncology (DGHO), Vienna (1994)
Professional Memberships
- German Society for Hematology and Medical Oncology (DGHO)
- European Hematology Association (EHA)
- American Society of Hematology (ASH)
- European Society for Blood and Marrow Transplantation (EBMT)
- International Society for Cellular Therapy (ISCT)
- Bavarian Cancer Research Center (BZKF) — Active President & Founding Director
Research & Publications
Published Papers (Selected)
- Mackensen A, Müller F, Mougiakakos D, Boeltz S, Wilhelm A, Aigner M, et al. CD19 CAR T-Cell Therapy in Refractory Systemic Lupus Erythematosus. Nature Medicine. 2022.
- Mackensen A, Schett G, et al. CAR-T Cell Therapy for Severe Autoimmune Diseases — CASTLE Study Update.
- Mackensen A, et al. Microglia and Mechanisms of ICANS in CD19-Directed CAR-T Cell Therapy.
- Mackensen A, et al. CD19-Directed CAR-T Cell Therapy in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma — Toxicity and Efficacy.
- Mackensen A, et al. Single-Cell RNA-Seq and T/B Cell Repertoire Analysis in Systemic Lupus Erythematosus.
- Mackensen A, et al. Preclinical Development of CAR-T Cells with Antigen-Inducible IL-18 Enforcement to Treat GD2-Positive Solid Cancers.
- Mackensen A, et al. Double CAR-T Cell Therapy for Rare Autoimmune Disease — Erlangen Case Report (2025).
Ongoing Research & Clinical Interests
- CAR-T cell therapy for hematological malignancies (lymphoma, myeloma, leukaemia)
- CAR-T cell therapy for severe autoimmune diseases (lupus, systemic sclerosis, myositis)
- Cytokine-armoured (IL-18) and dual-target CAR-T cells
- CAR-T cell therapy for solid tumours (GD2-positive)
- Allogeneic stem-cell transplantation, GvHD & GvL biology (TRR221)
- Mechanisms of ICANS and CRS in cellular immunotherapy
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (EUR) | Estimated Cost (USD) |
|---|---|---|
| Hematology / Oncology Consultation | €350 – €700 | $380 – $760 |
| Multidisciplinary Tumour Board Review | €700 – €1,800 | $760 – $1,960 |
| Comprehensive Molecular & Cytogenetic Workup | €2,500 – €6,000 | $2,700 – $6,500 |
| Standard Chemotherapy (per cycle) | €2,500 – €8,000 | $2,700 – $8,700 |
| Targeted / Immunotherapy (per month) | €5,000 – €15,000 | $5,400 – $16,300 |
| Autologous Stem-Cell Transplantation | €80,000 – €130,000 | $87,000 – $141,000 |
| Allogeneic Stem-Cell Transplantation | €150,000 – €280,000 | $163,000 – $304,000 |
| CAR-T Cell Therapy (per course, indicative) | €280,000 – €350,000 | $304,000 – $380,000 |
| Early-Phase Clinical Trial (Investigational Drug) | Often Trial-Funded | Often Trial-Funded |
| Inpatient Hematology / SCT Stay (per day) | €800 – €2,200 | $870 – $2,400 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Prof. Dr. med. Andreas Mackensen use in Hematologist treatment?
Prof. Dr. med. Andreas Mackensen employs the latest evidence-based tools and minimally invasive techniques relevant to Hematologist. Virtual consultations and remote second opinions are also available to international patients. Contact Cancer Rounds for a detailed technology overview specific to your case.
2. What conditions does Prof. Dr. med. Andreas Mackensen specialize in treating?
Prof. Dr. med. Andreas Mackensen is a specialist in Hematologist, treating a broad spectrum of conditions in this field — including both common presentations and complex, rare cases. International patients seek treatment for conditions requiring expert Hematologist care in Erlangen, Germany.
3. How do I book an appointment with Prof. Dr. med. Andreas Mackensen?
Appointments with Prof. Dr. med. Andreas Mackensen can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Prof. Dr. med. Andreas Mackensen?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Prof. Dr. med. Andreas Mackensen, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Prof. Dr. med. Andreas Mackensen offer second opinions for Hematologist cases?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with an expert Hematologist specialist in Erlangen, Germany.
Blood Cancer
